These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes.
    Author: Wang Y, Tomlinson B.
    Journal: Curr Opin Investig Drugs; 2007 Oct; 8(10):849-58. PubMed ID: 17907062.
    Abstract:
    Metabasis Therapeutics Inc (formerly Gensia Sicor Inc, which became SICOR Inc), in collaboration with Daiichi Sankyo Co Ltd (formerly Sankyo Co Ltd) is developing the fructose-1,6-bisphosphatase inhibitor managlinat dialanetil, a low-molecular weight purine nucleotide analog that inhibits gluconeogenesis, for the potential treatment of type 2 diabetes. Phase II clinical trials of the compound are underway in Europe and the US.
    [Abstract] [Full Text] [Related] [New Search]